Since adiponectin and leptin have been reported to have opposing activities on breast cancer progression, we also assessed whether their ratio might provide an index of intervention effectiveness but found that the variability of the ratio makes it problematic in this regard. The gene discussed is ADIPOQ; the disease is breast carcinoma.